Grifols, ES0171996087

Grifols stock: Board backs US business IPO to reduce debt

Published on 11/12/2026 at 11:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock gained a debt-reduction angle after the board backed a minority IPO of its US business. The proceeds are intended to help pay down debt.

US IPO Could Support Deleveraging

Grifols' board backed a plan to sell a minority stake in the US business.
The proposed transaction is intended to help reduce debt.
The plan adds a potential balance-sheet catalyst after recent earnings coverage focused on cash generation and leverage.

Grifols, ES0171996087, Illustration mit AI erstellt.

Grifols' board has backed a plan to sell a minority stake in the company's US business through an initial public offering, according to Pharmaphorum on Thursday, November 12, 2026. The Spanish plasma medicine specialist intends to use the IPO to help pay down debt.

The plan would give Grifols access to equity capital while retaining a majority stake in the US operation. That structure could support deleveraging without a full disposal of the business, although the financial impact will depend on the stake sold and the eventual valuation.

Potential Balance-Sheet Catalyst

For investors, the proposal adds a financing option to Grifols' broader debt-reduction effort. A successful listing could improve financial flexibility and provide a market reference for the US business. It could also leave the company exposed to execution risk, including market conditions, transaction timing and investor demand.

The announcement follows a series of recent company updates centered on stronger cash generation, lower leverage and unchanged full-year guidance. The US IPO plan shifts part of the focus from operating performance to capital allocation, making progress toward the transaction an important issue for the stock.

Grifols stock traded at 11.61 euros on Lang & Schwarz at 11:48 CET on Thursday, November 12, 2026.